Crowdonomics
All companies
EO2 CONCEPTS logo

EO2 CONCEPTS

Operating

Electrochemical Oxygen Concepts, Inc.

Healthcare · Technology · San Antonio, TX · Founded 2007

Oxygen-enhanced technology for advanced wound healing and skin support

Post-money valuation ⓘ
$79.3M
As of Aug 2023 · from Reg CF Offering (2022) · pre-money + amount raised, not a traded price
Total raised
$22,123,881
Crowd $742K · Private $21.4M · 12 rounds since 2008
Latest share price
$1.59
Reg CF · Preferred Stock · Nov 2022 offering price

Financials

FY2020–FY2025 · from SEC filings · hover any figure for its source
$1.5M
−$2.7M
2020
$2.1M
−$2.5M
2021
$3.8M
−$2.7M
2022
$6.4M
−$3.7M
2023
$5.7M
−$4.2M
2024
$4.1M
−$722K
2025
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2020 reviewed
FY2021 reviewed
FY2022 reviewed
FY2023 reviewed
FY2024 unaudited
FY2025
Income statement
Revenue
$1,450,379
$2,130,220
$3,761,573
$6,401,908
$5,723,605
$4,143,000
Cost of goods sold
$346,961
$640,373
$778,225
$691,453
$729,062
$86,222
Gross margin
76%
70%
79%
89%
87%
98%
Net income
-$2,692,694
-$2,517,980
-$2,738,366
-$3,670,123
-$4,189,401
-$722,240
Taxes paid
$0
$0
$0
$0
$0
$3,984
Balance sheet
Cash
$219,385
$72,823
$606,116
$221,966
$233,493
$46,530
Accounts receivable
$489,583
$1,024,322
$1,006,778
$2,768,886
$0
$3,366,808
Total assets
$1,477,228
$1,719,463
$3,568,756
$5,474,111
$22,502,217
$3,923,424
Short-term debt
$900,240
$1,386,548
$210,819
$2,443,072
$2,492,313
$2,492,313
Long-term debt
$2,707,598
$4,446,595
$7,799,257
$12,200,041
$0
$21,153,046
Total liabilities
$3,607,838
$5,833,143
$8,010,076
$14,643,113
$2,492,313
$23,645,359
Other
Headcount
—
22
22
19
9
22

Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited, as the filing’s own report or certification states it. A dashed pill marked * is inferred instead: the SEC minimum for an offering that size, which the issuer may have exceeded. No pill means we couldn’t tell. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.

Valuation over rounds

Pre-money — the valuation set before each round’s money came in
$78.4M
pre-money
Reg CF · Preferred · Nov 2022

Blue bars are the pre-money valuation the company stated for a priced round.

Share price over rounds

$1.59$0.795$1.00
Jan 2021Nov 2022
Round offering price or verified disclosed saleDisclosed sale, unverified or year-only

Disclosed sales come from the issuer's own filings (prior-offering lines, audited-statement notes) and are amount ÷ securities sold. A down round is a firm point more than 25 % below the previous firm point of the same share class on a comparable basis; the comparison ignores unverified and year-only lines.

Cap table

Share counts as of Apr 28, 2026
ClassOutstandingVotes / shareShare of totalLast price
Common Stock53,837,3961100.0%$1.59Nov 2022

Principal holders% as the filing states it, Apr 28, 2026

  • Van G Miller Revocable Trust10,775,293 Common Stock21.7%of company
  • Van G Miller Estate8,302,906 Common Stock16.7%of company
  • Everyone else (not named in filings)61.6%

Sold to the crowd

From the company's SEC filings: share counts per class, each class's voting and conversion terms, and the holders of 20% or more that Form C requires (officers and 10%+ holders on Form 1-A). Filings name only large holders, so most owners — including crowd investors — are not listed, and a holder's percentage may be of its own class rather than of the whole company. Prices and crowd share counts are in today's share terms — adjusted for splits and conversions since they were sold. Hover a figure for its filing.

Fundraising history

Raised $742.4K / $1.2MInvestors 272Post-money $79.3M
Raised $370KInvestors 7
Raised $500KInvestors 1
Raised $500KInvestors 1
Raised $500KInvestors 1
Raised $2.3MInvestors 1
Raised $8.7MInvestors 16
Raised $907.5KInvestors 2
Raised $70KInvestors 2
Raised $4.3MInvestors 47
Raised $2.5MInvestors 65
Raised $732.5KInvestors 21

Team

15 people
Mark Niederauer
President, CEO, Board Member

Dr. Niederauer has served as the Company’s Chief Technology Advisor since June of 2008, has served as the Chief Technology and Operating Officer since January of 2010 and became the President and CEO in August of 2021. He has more than 25 years of experience in commercialization, engineering, product development and manufacturing of pharmaceuticals medical devices, including regulatory and quality compliance. Dr. Niederauer has worked for Bayer Chemikalien in Leverkusen, Germany, Hoechst Celanese in Corpus Christi, TX, and for OsteoBiologics, Inc. (OBI) in San Antonio, TX, which was the acquired by Smith & Nephew Endoscopy. Dr. Niederauer earned a PhD in Biochemical Engineering, with a focus in Genetics, from Iowa State University. He is also a Fulbright Scholar, earning the equivalent of a Master of Science degree from environmental engineering work at the Universität Stuttgart in Germany. Dr. Niederauer has co-authored numerous articles and presentations and is a co-inventor on multiple patents.

Tony Gallardo
Chief Financial Officer & Secretary

Tony is a Certified Public Accountant with over years of financial and operational experience. He has overall responsibility for business financial operations including treasury, budgeting, forecasting, accounting management and human resources. Tonyhas worked as COO and CFO for entrepreneurial companies in home health care and mental health. With over years of experience Tony is adept at improving processes,including financial reporting, cash flow, internal controls and compliance with contract and regulatory requirements.As a financial leader Tony has extensive experience with budgeting and forecasting. He has guided operational teams to successfully prepare and exceed budgets. Additionally,over his career he has successfully guided the accounting team to set up the internal controls and processes for high growth companies.Tony earned his Bachelors degree in accounting from the University of Texas at SanAntonio.

Cyndi Gilliam, BSN, RN, FACCWS
Director of Clinical Affairs

Mrs. Gilliam is the Director of Clinical Affairs for EO2. She has worked as an industry Clinical Specialist for the last 10 years, including experience at Kinetic Concepts Inc. Her experience and expertise as a wound care RN has been instrumental in the relationships and educational programs she has built throughout the years. She has excellent contacts across the country within wound care, colorectal surgery, orthopedic, and other specialties. Her passion is integrating her business knowledge with her clinical knowledge to achieve the greatest outcomes for both her patients and clinicians, while achieving success for the company. She is excited to bring her knowledge and skills to help bring EO2 to the forefront of wound care as a standard of care therapy system.

Dave Kazynski
Exec. VP of Sales and Marketing, Board Member

Mr. Kazynski is the President of VGM’s HOMELINK business which is a insurance network contractor for a wide range of various healthcare services for members of VGM’s independent Durable Medical Equipment suppliers. HOMELINK has about 110 different managed care contracts. He served many years as a CFO and COO to a number of proprietary hospitals in IA and MO including a hospital sold to Tenet. Mr. Kazynski has been a member on the Center for Medicare Services DME Program Advisory and Oversight Committee (PAOC) and functioned as the hospital liaison for local Managed Care Plans. Mr. Kazynski graduated from the University of Northern Iowa in 1979 with a B.A. in Psychology, and then earned an M.B.A. in Finance in 1981.

James P. Daley
Director of Operations

Mr. Daley has over 45 years’ experience in electrical and mechanical engineering, manufacturing and product development in the fields of medical devices and aerospace. He oversees the research, design, manufacturing, packaging and testing of products. Mr. Daley also manages all plant operations, including shipping & receiving and facility maintenance. Mr. Daley is a co-inventor on multiple patents.

David Kazynski
Executive VP of Sales and Marketing and Board of Directors Member
Donna Hunt
Business Manager and Assistant Secretary

Donna has over 25 years of financial and operational experience in various industries, including medical devices, finance, banking and construction. Donna manages several components of EO2’s business, including accounting, human resources, logistics,document control and facility management. Prior to joining EO2, she worked for a startup medical device company, Bluegrass Vascular Technologies, as the Business Manager until they were recently acquired. Her prior work experience was primarily in banking in various financial and executive support roles for Wells Fargo and Frost Bank.

Joseph Monosmith
Quality Assurance Manager

Mr. Monosmith is the Quality Assurance Manager for EO2, with 13 years of experience in the Medical Device field. He has experience in manufacturing, assembly, shipping/receiving, quality control and quality assurance. In the medical device space, he previously worked in manufacturing and quality for the Endoscopy Division of Smith & Nephew. He is dedicated to, and strongly believes in, the innovation that EO2 brings to wound care, as well as, the positive impact to the quality of life for the patient population.

Kate Biasiolli
Marketing Manager

Mrs. Biasiolli currently holds position as both regional account manager in Texas as well as marketing manager. She has vast experience with in the wound care industry spanning over 15 years. During her tenure at the largest negative pressure wound therapy company, Kinetic Concepts Inc, Mrs. Biasiolli planned, developed and executed customer training throughout the globe while managing her team and million dollar budget. Her honors degree in biology combined with a certificate in adult education provides her a strong background to grasp complex processes and simplify into easy to understand, relatable concepts.

Show 6 more people
Peter Smith
Chairman of the Board of Directors

Mr Smith served as the Chief Operating Officer of Baxter's Japanese Subsidiary located in Tokyo and later was the President of Baxter's Caremark Division. He founded and led CorSolutions, a disease management company. Subsequently, he also founded and led Medmark, a specialty pharmaceutical distribution business. He currently sits on the Board of four other privately held healthcare companies. Mr Smith received his AB from Princeton University and his MBA from the University of Chicago.

Justin Cypert
Controller
Lewis Peter Smith
Chairman of the Board
Jim DeYoung
Board Member

Mr. DeYoung is founder and a principal of Winston Partners Incorporated, which provides strategic corporate advisory and investor relations services to private and public companies. In addition, Mr. DeYoung is a member of the management of DW Investments, LLC. Mr. DeYoung formerly was a general partner of Resource Ventures L.P. He was responsible for several of the fund’s investments. He served at Baxter International, Inc. in marketing, investor relations, public relations and corporate financial management functions. He is a Trustee of Rush University Medical Center and serves on the Executive, Investment and Information Technology Committees of the Board. Mr. De Young serves on a number of boards in the Chicago area. Mr. DeYoung is a graduate of Washington and Lee University (B.A.) and received his J.D. degree from Northwestern University School of Law.

Ken Melani, MD
Board member

Dr. Melani is currently the owner of KRM Group LLC, a healthcare consulting firm, and managing director of Velocity Fund Partners LLC, a life sciences venture capital fund. He started his career as a practicing Internist where he founded and later became Chairman and CEO of a physician-hospital organization called West Penn Cares. Over the next twenty-five years he served in a variety of executive leadership roles at Highmark Inc, culminating as the President and CEO from 2003-2012. He was credited with growing Highmark into one of the leading healthcare companies in the United States and personally regarded as one of the top healthcare executives in the country. Dr. Melani received his BA from Washington and Jefferson College, where he graduated Summa Cum Laude, and went on to receive a Doctorate of Medicine from The Wake Forest University School of Medicine.

James W. DeYoung
Board Member

Names and titles as disclosed on SEC Form C, StartEngine. Bios and photos come from the platform campaign page and may be out of date.

Reg CF annual-report compliance

Not requiredFewer than 300 holders of record

Filed 4 of 4 annual reports (FY2022–FY2025)

272 investors
holder-count proxy

Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.

  • Form C-ARApr 28, 20260001436343-26-000002
    EDGAR
  • Form C-ARApr 30, 20250001665160-25-000894
    EDGAR
  • Form C-ARApr 26, 20240001665160-24-000582
    EDGAR
  • Form C-USep 8, 20230001665160-23-001734
    EDGAR
  • Form C/AJun 15, 20230001665160-23-001399
    EDGAR
  • Form C-ARApr 28, 20230001665160-23-001019
    EDGAR
  • Form C/AApr 28, 20230001665160-23-000977
    EDGAR
  • Form C/AApr 10, 20230001665160-23-000573
    EDGAR
Source: ManualCIK 0001436343DEShare price $1.59

About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.